Walvax Biotechnology Co., Ltd.
300142
Rang in Aktien
#4861
Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical... Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.
Aktienkurs
$1.87
Marktkapitalisierung
$2.98B
Veränderung (1 Tag)
-3.71%
Veränderung (1 Jahr)
14.73%
Land
CN
Handel Walvax Biotechnology Co., Ltd. (300142)
Kategorie
Healthcare
Gewinn für Walvax Biotechnology Co., Ltd. (300142)
Gewinn im Jun 2026 TTM: $33.43M
Laut den aktuellen Finanzberichten von Walvax Biotechnology Co., Ltd. betragen die aktuellen Gewinne des Unternehmens $33.43M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $25.28M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2023, der $84.62M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Walvax Biotechnology Co., Ltd. von 2007 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $33.43M | 40.82% |
| 2025 | $23.74M | -6.07% |
| 2024 | $25.28M | -70.13% |
| 2023 | $84.62M | -45.47% |
| 2022 | $155.19M | 39.13% |
| 2021 | $111.54M | -46.94% |
| 2020 | $210.22M | 537.94% |
| 2019 | $32.95M | -80.85% |
| 2018 | $172.06M | -294.12% |
| 2017 | $-88.63M | -1,874.21% |
| 2016 | $5.00M | -103.67% |
| 2015 | $-136.24M | -711.67% |
| 2014 | $22.27M | 1,211.52% |
| 2013 | $1.70M | -96.04% |
| 2012 | $42.89M | 9.96% |
| 2011 | $39.01M | 40.55% |
| 2010 | $27.75M | 101.15% |
| 2009 | $13.80M | 117.38% |
| 2008 | $6.35M | 390.06% |
| 2007 | $1.30M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $3.62B | 10,720.80% |
DE
|
|
| $3.40B | 10,084.09% |
DE
|
|
| $1.72B | 5,055.23% |
JP
|
|
| $930.30M | 2,682.47% |
CH
|
|
| $1.76B | 5,177.67% |
IN
|
